Led by its diabetes lineup, Novo Nordisk could continue to deliver solid returns in 2020.
News & Analysis: Novo Nordisk
Last week, Weight Watchers International rolled out myWW, offering members a customized approach to weight management. But will its new program and its rebranding effort help it recover from slimmer third-quarter revenue results?
The small-cap biopharma inked a deal with a major pharmaceutical company, its second in three weeks.
NVO earnings call for the period ending September 30, 2019.
Which stock wins in a battle between these two healthcare giants?
GLP-1 drugs keep getting easier to take.
Here's what investors need to know about a new injection-free, non-insulin treatment for type 2 diabetes.
These two businesses could receive a big boost this month if certain events fall in their favor.
The second quarter wasn't too shabby either.
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.